<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="the Americas, with recent epidemics occurring on both continents. The" exact="yellow fever" post="vaccine is effective, affordable and safe, providing life-long immunity"/>
 <result pre="epidemics, but there are no randomized controlled trials of fractional" exact="yellow fever" post="vaccine doses in Africa. Methods and analysis: We will"/>
 <result pre="will be randomized to receive fractional or standard doses of" exact="yellow fever" post="vaccine. Scheduled visits will include blood collection for serum"/>
 <result pre="least eight years. WHO recommends the use of fractional dose" exact="yellow fever" post="vaccination as an off-label use in response to emergency"/>
 <result pre="key questions the trials are answering? Can all four WHO-prequalified" exact="yellow fever" post="vaccines be used as fractional doses with non-inferior immunogenicity"/>
 <result pre="compared to the standard vaccine dose? What is the minimum" exact="yellow fever" post="vaccine dose that is non-inferior to the standard dose?"/>
 <result pre="is non-inferior to the standard dose? Can reduced doses of" exact="yellow fever" post="vaccine provide sufficient immunogenicity in infants and children under"/>
 <result pre="under the age of 5 years? Are reduced doses of" exact="yellow fever" post="vaccine sufficiently immunogenic in human immunodeficiency virus (HIV)-infected individuals"/>
 <result pre="longevity of the immunity provided by the reduced doses of" exact="yellow fever" post="vaccine? Introduction Yellow fever (YF) is caused by a"/>
 <result pre="few days after vaccination. Serious reactions are rare and include" exact="hypersensitivity" post="reactions to components of the vaccine, YF vaccine-associated neurologic"/>
 <result pre="symptomatic HIV/AIDS or other causes, known thymus disorder, such as" exact="thymoma" post="and myasthenia gravis and acute febrile diseases • Previous"/>
 <result pre="or other causes, known thymus disorder, such as thymoma and" exact="myasthenia gravis" post="and acute febrile diseases • Previous YF vaccination •"/>
 <result pre="doses - June 2017, addendum to vaccines and vaccination against" exact="yellow fever" post="WHO: Position paper - June 2013.Vaccine.2017;35(43):5751–5752. 10.1016/j.vaccine.2017.06.08728689653 2collab: SAGE"/>
 <result pre="paper - June 2013.Vaccine.2017;35(43):5751–5752. 10.1016/j.vaccine.2017.06.08728689653 2collab: SAGE WHO: Fractional dose" exact="yellow fever" post="vaccine as a dose-sparing option for outbreak response.2016Reference Source"/>
 <result pre="dose-sparing option for outbreak response.2016Reference Source 3MutebiJPBarrettAD: The epidemiology of" exact="yellow fever" post="in Africa.Microbes Infect.2002;4(14):1459–68. 10.1016/s1286-4579(02)00028-x12475636 4ShearerFMLongbottomJBrowneAJet al.: Existing and potential"/>
 <result pre="10.1016/s1286-4579(02)00028-x12475636 4ShearerFMLongbottomJBrowneAJet al.: Existing and potential infection risk zones of" exact="yellow fever" post="worldwide: a modelling analysis.Lancet Glob Health.2018;6(3):e270–e278. 10.1016/S2214-109X(18)30024-X29398634 5MonathTPVasconcelosPF: Yellow"/>
 <result pre="Fever, jaundice, and multiple organ system failure associated with 17D-derived" exact="yellow fever" post="vaccination, 1996-2001.MMWR Morb Mortal Wkly Rep.2001;50(30):643–5. 11787575 9GarskeTVan KerkhoveMDYactayoSet"/>
 <result pre="Virus Res.2003;60:343–95. 10.1016/s0065-3527(03)60009-614689698 11GotuzzoEYactayoSCórdovaE: Efficacy and duration of immunity after" exact="yellow fever" post="vaccination: systematic review on the need for a booster"/>
 <result pre="One.2016;11(3):e0149871. 10.1371/journal.pone.014987126977808 13MonathTP: Review of the risks and benefits of" exact="yellow fever" post="vaccination including some new analyses.Expert Rev Vaccines.2012;11(4):427–48. 10.1586/erv.12.622551029 14FoxJPPennaHA:"/>
 <result pre="some new analyses.Expert Rev Vaccines.2012;11(4):427–48. 10.1586/erv.12.622551029 14FoxJPPennaHA: Behavior of 17D" exact="yellow fever" post="virus in rhesus monkeys: relation to substrain, dose and"/>
 <result pre="controlling the disease.Vaccine.2017;35(44):5951–5955. 10.1016/j.vaccine.2017.03.03228366605 16Osei-KwasiMDunyoSKKoramKAet al.: Antibody response to 17D" exact="yellow fever" post="vaccine in Ghanaian infants.Bull World Health Organ.2001;79(11):1056–9. 11731813 17BeckASBarrettAD:"/>
 <result pre="Health Organ.2001;79(11):1056–9. 11731813 17BeckASBarrettAD: Current status and future prospects of" exact="yellow fever" post="vaccines.Expert Rev Vaccines.2015;14(11):1479–92. 10.1586/14760584.2015.108343026366673 18FergusonMShinJKnezevicIet al.: WHO Working Group"/>
 <result pre="Switzerland, 13-14 May 2009.Vaccine.2010;28(52):8236–45. 10.1016/j.vaccine.2010.10.07021055492 19WuJTPeakCMLeungGMet al.: Fractional dosing of" exact="yellow fever" post="vaccine to extend supply: a modelling study.Lancet.2016;388(10062):2904–2911. 10.1016/S0140-6736(16)31838-427837923 20BarrettAD:"/>
 <result pre="- Preliminary Report.N Engl J Med.2018Reference Source 22MonathTP: Stability of" exact="yellow fever" post="vaccine.Dev Biol Stand.1996;87:219–25. 8854020 23collab: World Health Organization (WHO):"/>
 <result pre="to assure the quality, safety and efficacy of live attenuated" exact="yellow fever" post="vaccines (Annex 5).2013Reference Source 24collab: PATH: Yellow Fever vaccination:"/>
 <result pre="(PAHO): Epidemiological Update: Yellow Fever.2018Reference Source 29MartinsRMMaia MdeLFariasRHet al.: 17DD" exact="yellow fever" post="vaccine: a double blind, randomized clinical trial of immunogenicity"/>
 <result pre="Vaccin Immunother.2013;9(4):879–88. 10.4161/hv.2298223364472 30Campi-AzevedoACde Almeida EstevamPCoelho-Dos-ReisJGet al.: Subdoses of 17DD" exact="yellow fever" post="vaccine elicit equivalent virological/immunological kinetics timeline.BMC Infect Dis.2014;14:391. 10.1186/1471-2334-14-39125022840"/>
 <result pre="virological/immunological kinetics timeline.BMC Infect Dis.2014;14:391. 10.1186/1471-2334-14-39125022840 31RoukensAHVossenACBredenbeekPJet al.: Intradermally administered" exact="yellow fever" post="vaccine at reduced dose induces a protective immune response:"/>
 <result pre="controlled non-inferiority trial.PLoS One.2008;3(4):e1993. 10.1371/journal.pone.000199318431480 32Lopes OdeSGuimarãesSSde CarvalhoR: Studies on" exact="yellow fever" post="vaccine. III--Dose response in volunteers.J Biol Stand.1988;16(2):77–82. 10.1016/0092-1157(88)90034-03372545 33VanniceKWilder-SmithAHombachJ:"/>
 <result pre="Advancing the Evidence Base.N Engl J Med.2018;379(7):603–605. 10.1056/NEJMp180343329995585 34RoukensAHEVisserLG: Fractional-dose" exact="yellow fever" post="vaccination: an expert review.J Travel Med.2019;26(6):pii: taz024. 10.1093/jtm/taz02430937437 35GoujonCGougeonMLTondeurLet"/>
 <result pre="al.: CHRONOVAC VOYAGEUR: A study of the immune response to" exact="yellow fever" post="vaccine among infants previously immunized against measles.Vaccine.2017;35(45):6166–6171. 10.1016/j.vaccine.2017.09.04728958813 36Luiza-SilvaMCampi-AzevedoACBatistaMAet"/>
 <result pre="al.: Cytokine signatures of innate and adaptive immunity in 17DD" exact="yellow fever" post="vaccinated children and its association with the level of"/>
 <result pre="antibody.J Infect Dis.2011;204(6):873–83. 10.1093/infdis/jir43921849284 37SidibeMYactayoSKalleAet al.: Immunogenicity and safety of" exact="yellow fever" post="vaccine among 115 HIV-infected patients after a preventive immunisation"/>
 <result pre="Uganda.figshare.201910.6084/m9.figshare.10283048.v2 40CohenBJDoblasDAndrewsN: Comparison of plaque reduction neutralisation test (PRNT) and" exact="measles" post="virus-specific IgG ELISA for assessing immunogenicity of measles vaccination.Vaccine.2008;26(50):6392–7."/>
 <result pre="(PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of" exact="measles" post="vaccination.Vaccine.2008;26(50):6392–7. 10.1016/j.vaccine.2008.08.07418834911 41WietenRWJonkerEFPierenDKet al.: Comparison of the PRNT and"/>
 <result pre="Comparison of the PRNT and an immune fluorescence assay in" exact="yellow fever" post="vaccinees receiving immunosuppressive medication.Vaccine.2016;34(10):1247–51. 10.1016/j.vaccine.2016.01.03726845742 42DomingoCPatelPYillahJet al.: Advanced yellow"/>
 <result pre="yellow fever vaccinees receiving immunosuppressive medication.Vaccine.2016;34(10):1247–51. 10.1016/j.vaccine.2016.01.03726845742 42DomingoCPatelPYillahJet al.: Advanced" exact="yellow fever" post="virus genome detection in point-of-care facilities and reference laboratories.J"/>
 <result pre="external quality assessment study on molecular and serological methods for" exact="yellow fever" post="diagnosis.PLoS One.2012;7(5):e36291. 10.1371/journal.pone.003629122570700 44FullertonTForrestALevyG: Pharmacodynamic analysis of sparse data"/>
</results>
